| Managing the CRC
Board
An independent Board governs the CRC.
Find out more about the Board
Scientific/Commercialisation Advisory Committee
The independent Scientific/Commercialisation Advisory Committee ensures that scientific goals are obtained through high quality competitive research and that the research is optimised to achieve valuable outcomes through expert commercial assistance and advice.
The members of the Committee are:
- Dr Andy Gearing (Chair), Commercial, CEO Biocommsquared, Monash Medical Centre
Monash Institute of Medical Research
- Dr John Flack, CEO, CRC for Chronic Inflammatory Diseases
- Dr Lena Mårtensson, Commercial, AstraZeneca representative, Respiratory and Inflammation Research Area, AstraZeneca R&D, UK
- Professor Luke O’Neill, Biochemistry Department, Trinity College, Dublin, Ireland
- Associate Professor Patrick McNeil, Faculty of Medicine, University of New South Wales; Department of Medicine, Prince of Wales Clinical School
- Professor Doug Hilton, Senior Principal Research Fellow and Head Division of Molecular Medicine, The Walter and Eliza Hall Institute For Medical Research
- Professor Les Cleland, Director, Department of Rhematology, Royal Adelaide Hospital
- Professor Paul Foster, Director, Asthma, Allergy and Inflammation Research Centre, School of Biomedical Sciences, Faculty of Health, University of Newcastle
- Ms Robyn McLachlan (Ex officio), COO, CRC for Chronic Inflammatory Diseases
Executive Committee One
The Executive Committee is the major operational committee of the CRC. It monitors the internal operations of research Programs 1-3 and 5, checking resource levels compared with research and education progress and identifying further opportunities for integration of skills and for cooperation. The Committee also observes research and commercial activities in the external community for possible impacts on the CRC.
The members are:
- Dr John Flack, (Chair), CEO, CRC for Chronic Inflammatory Diseases
- Professor John Hamilton, Laboratory Head, Department of Medicine, The University of Melbourne
- Professor Gary Andersonn, Laboratory Head, Department of Pharmacology, The University of Melbourne
- Professor Paul Hertzog, Laboratory Head, Monash University
- Dr Matthew Sweet, Laboratory Head, The University of Queensland
- Dr Lena Martensson, Director Discovery Alliances & Competitive Intelligence, Respiratory and Inflammation Research Area, AstraZeneca R&D, UK
- Ms Robyn McLachlan (Ex officio), COO, CRC for Chronic Inflammatory Diseases
- Associate Professor Stuart Kellie (ex officio) Deputy CEO
Executive Committee Two
The Program 4 research program into joint prostheses is managed separately from the other research programs. One of the CRC’s new commercial supporting partners, Zimmer, has rights to specified intellectual property developed from this research.
The committee members are:
- Dr John Flack, (Chair), CEO, CRC for Chronic Inflammatory Diseases
- Dr Ian Cassady, Program 4 Co-Program Leader
- Dr Ross Garrett, Director Bone and Drug Device R&D, Zimmer Inc
- Professor John Hamilton, CRC for Chronic Inflammatory Diseases
InflaMac Pty Ltd
Centre Intellectual Property (Centre IP) generated through the life of the CRC is held by our management company, InflaMac Pty Ltd, in trust for the University Participants. InflaMac is responsible for the commercialisation of Centre IP in accordance with the CRC’s Centre and Commonwealth Agreements. It markets Centre IP to industry by seeking potential licensees of the Centre IP and presents such commercialisation options to the CRC’s Governing Board. If required by the University Participants, InflaMac will negotiate on behalf of the University Participants with the CRC’s commercial partners in relation to Centre IP. InflaMac’s directors are Dr John Flack (Managing Director), Dr Peter Isdale and Dr David Cookson. The Company Secretary is Ms Robyn McLachlan. |
